More On

Court denies AstraZeneca’s bid to block generic Seroquel

Company failed to show it was entitled to “extraordinary remedy” of an injunction

On Friday, a district court denied biopharmaceutical company AstraZeneca’s request for a preliminary injunction that would delay generic versions of its anti-psychotic drug Seroquel from entering the market.

London-based AstraZeneca’s patent for Seroquel expires today, March 26, and generics of the instant-release form are due to hit the U.S. market today as well. AstraZeneca filed an injunction earlier in March that sought to keep the Food and Drug Administration from granting final approval of Seroquel’s generics until December.

Join the Conversation

Advertisement. Closing in 15 seconds.